Perspective Therapeutics (NYSE:CATX) Given Outperform Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research note released on Tuesday,RTT News reports. The brokerage currently has a $11.00 price objective on the stock.

A number of other equities analysts also recently weighed in on CATX. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research note on Monday, March 31st. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Scotiabank began coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Finally, Royal Bank of Canada decreased their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and an average price target of $12.75.

Perspective Therapeutics Stock Up 1.6%

NYSE CATX opened at $2.55 on Tuesday. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $19.05. The firm’s fifty day simple moving average is $2.25 and its 200-day simple moving average is $3.84.

Insider Buying and Selling

In other news, Director Robert F. Williamson III purchased 38,145 shares of the firm’s stock in a transaction on Monday, March 31st. The stock was bought at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the acquisition, the director now directly owns 108,982 shares of the company’s stock, valued at approximately $233,221.48. The trade was a 53.85% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Johan M. Spoor purchased 22,026 shares of the firm’s stock in a transaction on Friday, March 28th. The shares were purchased at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the acquisition, the chief executive officer now directly owns 59,383 shares of the company’s stock, valued at approximately $133,017.92. This trade represents a 58.96% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 115,696 shares of company stock worth $256,344. Corporate insiders own 3.72% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd bought a new stake in Perspective Therapeutics during the fourth quarter valued at about $33,000. Aigen Investment Management LP bought a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $34,000. National Bank of Canada FI lifted its stake in shares of Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after buying an additional 10,998 shares during the period. ProShare Advisors LLC lifted its stake in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after buying an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. bought a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $51,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.